Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

P2Y12 Inhibitor or Aspirin Monotherapy in Patients with Coronary Artery Disease: is it Time for a Paradigm Shift?

Author(s): Felice Gragnano*, Antonio Capolongo and Paolo Calabrò

Volume 22, Issue 1, 2024

Published on: 23 November, 2023

Page: [1 - 4] Pages: 4

DOI: 10.2174/0115701611269735231106110250

Next »
[1]
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407-77.
[http://dx.doi.org/10.1093/eurheartj/ehz425] [PMID: 31504439]
[2]
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol 2022; 79(2): e21-e129.
[http://dx.doi.org/10.1016/j.jacc.2021.09.006] [PMID: 34895950]
[3]
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
[http://dx.doi.org/10.1016/S0140-6736(09)60503-1] [PMID: 19482214]
[4]
Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A critical appraisal of aspirin in secondary prevention. Circulation 2016; 134(23): 1881-906.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023952] [PMID: 27920074]
[5]
Marcucci R, Berteotti M, Gragnano F, et al. Monitoring antiplatelet therapy: Where are we now? J Cardiovasc Med 2023; 24 (Suppl. 1): e24-35.
[http://dx.doi.org/10.2459/JCM.0000000000001406] [PMID: 36729588]
[6]
Capodanno D, Baber U, Bhatt DL, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol 2022; 19(12): 829-44.
[http://dx.doi.org/10.1038/s41569-022-00725-6] [PMID: 35697777]
[7]
Cesaro A, Gragnano F, Calabrò P, et al. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. Int J Cardiol 2021; 345: 7-13.
[http://dx.doi.org/10.1016/j.ijcard.2021.10.138] [PMID: 34695525]
[8]
Cesaro A, Taglialatela V, Gragnano F, et al. Low-Dose ticagrelor in patients with high ischemic risk and previous myocardial infarction: A multicenter prospective real-world observational study. J Cardiovasc Pharmacol 2020; 76(2): 173-80.
[http://dx.doi.org/10.1097/FJC.0000000000000856] [PMID: 32569017]
[9]
Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials. BMJ 2021; 373: n1332.
[http://dx.doi.org/10.1136/bmj.n1332] [PMID: 34135011]
[10]
Gragnano F, Zwahlen M, Vranckx P, et al. Ticagrelor monotherapy or dual antiplatelet therapy after drug-eluting stent implantation: Per-protocol analysis of the global leaders trial. J Am Heart Assoc 2022; 11(10): e024291.
[http://dx.doi.org/10.1161/JAHA.121.024291] [PMID: 35229616]
[11]
Gragnano F, Heg D, Franzone A, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the global leaders and glassy. Eur Heart J Cardiovasc Pharmacother 2022; 8(1): 28-38.
[http://dx.doi.org/10.1093/ehjcvp/pvaa106] [PMID: 32941620]
[12]
Gragnano F, Mehran R, Branca M, et al. P2Y12 Inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol 2023; 81(6): 537-52.
[http://dx.doi.org/10.1016/j.jacc.2022.11.041] [PMID: 36754514]
[13]
Kogame N, Guimarães PO, Modolo R, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable cad. JACC Cardiovasc Interv 2020; 13(19): 2251-62.
[http://dx.doi.org/10.1016/j.jcin.2020.06.023] [PMID: 32950419]
[14]
Natsuaki M. 26 August 2023: dual-antiplatelet therapy should remain standard strategy after stent implantation. Presented at European Society of Cardiology (ESC) congress 2023. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Dual-antiplatelet-therapy-should-remain-standard-strategy-after-stent-implantation
[15]
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[16]
Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021; 397(10293): 2487-96.
[http://dx.doi.org/10.1016/S0140-6736(21)01063-1] [PMID: 34010616]
[17]
Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: The host-exam extended study. Circulation 2023; 147(2): 108-17.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062770] [PMID: 36342475]
[18]
Gragnano F, Cao D, Pirondini L, et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol 2023; 82(2): 89-105.
[http://dx.doi.org/10.1016/j.jacc.2023.04.051] [PMID: 37407118]

Rights & Permissions Print Cite
Article Metrics
29
2
© 2024 Bentham Science Publishers | Privacy Policy